Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Eiger BioPharma: Q3 Earnings Snapshot AP - Thu Nov 9, 2023

Eiger BioPharma: Q3 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Wall Street - shutterstock_2269106477
Stocks Tread Water Before the Open as U.S. Inflation Data Looms Barchart - Wed Sep 13, 2023

September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...

AAP : 58.18 (+0.03%)
WRK : 51.51 (+3.54%)
NQU23 : 15,435.20s (-0.28%)
AAPL : 271.06 (-0.87%)
AV-.LN : 631.402 (-0.94%)
F : 12.38 (-0.80%)
WKHS : 2.67 (+0.38%)
ORCL : 173.28 (-1.70%)
ESU23 : 4,491.72s (-0.32%)
RCKT : 3.52 (-4.35%)
SQSP : 46.57 (-0.21%)
EIGR : 1.7250 (-9.21%)
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta PR Newswire - Tue Sep 12, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q2 Earnings Snapshot AP - Mon Aug 14, 2023

Eiger BioPharma: Q2 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO PR Newswire - Thu Jun 29, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow PR Newswire - Wed Jun 28, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q1 Earnings Snapshot AP - Thu May 11, 2023

Eiger BioPharma: Q1 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire - Thu May 11, 2023

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)

Barchart Exclusives

3 Under-the-Radar Dividend Stocks Yielding Up to 13% That Wall Street Rates a Strong Buy Barchart - Fri Apr 24, 6:00PM CDT
Three under-the-radar dividend stocks offer yields up to 13%, bullish analyst ratings, and possible upside for income investors seeking overlooked names. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.